NL-OMON40173CompletedNot Applicable
A SINGLE ORAL ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO6836191 IN HEALTHY MALE VOLUNTEERS INCLUDING A SINGLE INTRAVENOUS DOSE OF RO6836191 - RO6836191 SAD + FE study
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 96
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •18 to 45 years of age, inclusive
- •BMI between 18 to 30 kg/m2 inclusive
- •healthy male volunteers
Exclusion Criteria
- •suffering from hepatitis B, hepatitis C or HIV/AIDS
- •donation of blood over 450 mL within three months prior to screening
- •Participation in another investigational drug or device study within 3 months prior to dosing
Investigators
Similar Trials
Completed
Not Applicable
An escalating single oral dose trial investigating the safety, tolerance, pharmacokinetics and pharmacodynamics of orally administered Org 201745-0 in healthy sterilized women with normal ovulatory cyclesanticonceptiebirth controlcontraceptionNL-OMON30881Akzo Nobel (Organon)Orion Pharma48
Active, not recruiting
Phase 1
Single Dose Study of MK-2060 in Healthy Japanese ParticipantsPrevention of thrombotic vascular eventsJPRN-jRCT2031220658Tanaka Yoshiyuki48
Completed
Not Applicable
An open-label, single ascending dose study to evaluate the safety and pharmacokinetics of a tablet formulation of CG-549 in healthy subjectsbacterial infections10004018NL-OMON48209CrystalGenomics, Inc24
Recruiting
Phase 1
A phase I study of epinephrine sublingual tablet in healthy subjectsCTRI/2020/09/027808Belcher Pharmaceuticals
Completed
Phase 1
An Open-label, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LYN-163 in Healthy VolunteersInfection - Other infectious diseasesMalariaACTRN12621001218886yndra®Therapeutics, Inc. (Lyndra)15